SecBot SecBot
8-K ·Filed Aug 4, 2026

PFE

PFIZER INC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000078003-26-000094
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The beat-and-raise quarter supports the fundamental turnaround narrative driven by non-COVID product strength and cost discipline. The $4.3B impairment is non-cash and should not distract from operational momentum. For Q3, watch for the ~$0.10 Innovent EPS headwind and the trajectory of COVID product revenues. The CFO transition adds near-term overhang but appears orderly.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.41
T+0 close · Aug 4, 2026 · via day close
Latest settled
+17.28%
T+60 · $29.80
Vs SPY
+17.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $25.41entry
  2. T+1 · 3mo ago +1.57%α +1.77% · $25.81
  3. T+5 · 3mo ago +4.76%α +4.86% · $26.62
  4. T+20 · 3mo ago +12.36%α +13.60% · $28.55
  5. T+60 · 20d ago +17.28%α +17.49% · $29.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat vs $0.68 consensus) and revenue of $15.0B (4.5% beat vs $14.4B consensus), raised full-year 2026 revenue guidance by $500M midpoint to $60.5-$62.5B, and reaffirmed adjusted EPS guidance of $2.80-$3.00 despite absorbing a ~$0.10 impact from the Innovent biologics transaction. Strength in non-COVID products (Eliquis +19%, Padcev +23%, Lorbrena +37%) drove 18% operational growth in launched/acquired products, offsetting COVID revenue declines, while GAAP reported a net loss of $0.04 per share due to $4.3B in non-cash intangible asset impairments.

Key Financial Metrics

EPS
$0.77
est $0.68 · +13.2%
Revenue
$15.0B
est $14.4B · +4.5% · +3.0% YoY
Rating
strong beat
Guidance
$60.5 to $62.5 billion
raised

Key Facts

  • Adjusted diluted EPS of $0.77 beat consensus of $0.68 by 13.2%
  • Revenue of $15.034B rose 3% YoY (1% operational); ex-COVID, revenue grew 5% operationally
  • Full-year 2026 revenue guidance raised $500M at midpoint to $60.5-$62.5B; adjusted EPS guidance reaffirmed at $2.80-$3.00
  • GAAP reported a loss of $(0.04)/share due to $4.3B in non-cash intangible asset impairments (sigvotatug vedotin $3.8B, Oxbryta $525M)
  • Launched & Acquired Products grew 18% operationally; Eliquis +19%, Padcev +23%, Lorbrena +37%
  • COVID products Comirnaty and Paxlovid declined 34% and 95% operationally, respectively
  • Announced $1.0B additional cost savings in SIA and $1.5B in manufacturing optimization savings through 2029
  • Completed $1.875B exit of ViiV Healthcare stake in Q1; closed Innovent Biologics licensing deal on July 10 (recorded in Q3)
  • CFO Dave Denton to step down August 15; interim CFO Cecile Guegan appointed

Financial Impact

Adjusted EPS beat by 13% and revenue beat by 4.5%; revenue guidance raised by $500M at midpoint; impairments of $4.3B (non-cash) drive GAAP loss

revenueepsguidanceimpairmentscost savings

Risk Factors

  • Sustained COVID revenue decline could pressure overall growth as non-COVID products may not fully offset in future quarters
  • $4.3B asset impairments signal clinical setbacks (sigvotatug vedotin ADC, Oxbryta), raising pipeline risk
  • CFO departure introduces leadership uncertainty pending permanent replacement search
  • Adjusted EPS guidance unchanged despite revenue raise, reflecting dilution from Innovent deal and cost investments

Market Snapshot

Price
$25.25
Volume
200
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
42% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000078003-26-000094
Document: pfe-20260804.htm0000078003-26-000094
Document: 0000078003-26-000094-index-headers.html0000078003-26-000094
Document: 0000078003-26-000094-index.html0000078003-26-000094
Document: 0000078003-26-000094.txt0000078003-26-000094
8-K Data (Synthetic)0000078003-26-000094

Track record

21 reports on PFE

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +16.49% at T+60 after the Aug 5, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
  2. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
  3. Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
  4. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
  5. Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
  6. Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
  7. Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
  8. Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
  9. Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
  10. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (14h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026